Imatinib - New molecular treatment for chronic myeloid leukemia. The IRIS study

被引：2

作者：

Berger U. ^{[1
,2
]}

Hehlmann R. ^{[1
]}

机构：

[1] III. Medizinische Universitatsklinik, Klinikum Mannheim, Universität Heidelberg, Mannheim

[2] III. Medizinische Universitatsklinik, Klin. Mannheim der Univ. Heidelberg, 68305 Mannheim

来源：

Der Internist | 2004年 / 45卷 / 1期

关键词：

D O I：

10.1007/s00108-003-1085-3

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：102 / 103

页数：1

共 5 条

[1]

O'Brien S., Guilhot F., Larson R., Et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 348, pp. 994-1004, (2003)

[2]

Hasford J., Pfirrmann M., Hehlmann R., Et al., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha, J Natl Cancer Inst, 90, pp. 850-858, (1998)

[3]

Bonifazi F., DeVivo A., Rosti G., Et al., Chronic myeloid leukemia and interferon alpha: A study of complete cytogenetic responders, Blood, 98, pp. 3074-3081, (2001)

[4]

Hehlmann R., Current CML-therapy: Progress and dilemma, Leukemia, 6, (2003)

[5]

Merx K., Muller M.C., Kreil S., Et al., Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha, Leukemia, 16, pp. 1579-1583, (2002)

← 1 →